Impact of chronic kidney disease on toxicity patterns and economic burden in CAR T-cell therapy for multiple myeloma: A national analysis.

Journal of Clinical Oncology 2026

View at publisher
Authors: Himil J Mahadevia, Karnav Modi, Yajur Arya, Arshi Syal, Khaled M. El-Husseiny, Shivani Modi, Vasu Bansal, Deepthi Vodnala, Taiyeb Khumri, Furha Cossor
DOI: 10.1200/jco.2026.44.16_suppl.e19536
Cited by: 1

Abstract

e19536 Background: Chronic kidney disease (CKD) may impair physiologic resilience during chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma (MM). While cytokine response syndrome (CRS) and immune cell-associated neurotoxicity syndromes (ICANS) have been described in MM CAR-T recipients with CKD, the broader cardiopulmonary, infectious, renal, and economic implications of CKD remain insufficiently defined. We examined the national impact of CKD on mortality, immune cell effector toxicities, organ dysfunction, infections and resource utilization. Methods: Adult MM hospitalizations receiving CAR T-cell therapy were identified from the National Inpatient Sample (2018–2022) using ICD-10-PCS codes. Patients with ESRD were excluded. CKD was categorized as CKD3a+ (eGFR

Fields of Study & Subjects

CAR-T cell therapy research Multiple Myeloma Research and Treatments Cancer-related cognitive impairment studies

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
16_suppl
Publication date
28 May 2026
Language
EN